ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0409

Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies

Philip J Mease1, Atul Deodhar2, Maxime Dougados3, Maureen Dubreuil4, Marina Magrey5, Helena Marzo-Ortega6, Martin Rudwaleit7, Christine de la Loge8, Alicia Ellis9, Carmen Fleurinck10, Marga Oortgiesen11, Vanessa Taieb12 and Lianne Gensler13, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Oregon Health & Science University, Portland, OR, USA, Portland, OR, 3Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, 4Department of Rheumatology, Boston University School of Medicine, Boston, MA, 5Case Western Reserve University, University Hospitals, Richfield, OH, 6Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, 7University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 8UCB Pharma, Brussels, Belgium, 9UCB Pharma, Raleigh, 10UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, 11UCB Pharma, Raleigh, NC, 12UCB Pharma, Colombes, France, 13Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Patient reported outcomes, quality of life, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ improved signs and symptoms and reduced disease activity up to Week (Wk) 24 in patients (pts) with active non-radiographic axSpA (nr-axSpA) and active ankylosing spondylitis (AS; i.e. radiographic axSpA) in the phase 3 studies BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743), respectively; all primary and ranked secondary endpoints at Wk 16 were met, including change from baseline (CfB) in nocturnal spinal pain.1,2 Here, we evaluate the impact of BKZ in pts with nr-axSpA and AS on major contributors to disease burden (spinal pain, stiffness and fatigue)3 to Wk 24 in both studies.

Methods: BE MOBILE 1 and 2 were conducted in parallel and had similar designs, with a 16-wk double-blind period followed by a 36-wk maintenance period. Pts were randomized to BKZ 160 mg Q4W or placebo (PBO); all pts received BKZ 160 mg Q4W from Wk 16 onward.1,2 We report proportion of pts achieving selected thresholds at Wk 16 for low pain (total and nocturnal spinal pain score: ≤0/1/2/3/4) and improvement in fatigue (Functional Assessment of Chronic Illness [FACIT]-Fatigue score: ≥4-point increase from baseline [BL]) using non-responder imputation. Mean CfB to Wk 24 in total spinal pain, nocturnal spinal pain, BASDAI morning stiffness (mean of BASDAI questions 5 and 6), and FACIT-Fatigue scores are reported using multiple imputation.

Results: 254 pts with nr-axSpA (BKZ: 128; PBO: 126) and 332 with AS (BKZ: 221; PBO: 111) were randomized; 94.5% and 94.3% completed to Wk 24, respectively. Across both studies, mean BL scores for all reported outcomes indicated high symptom severity (Figure 1, 2).

A greater proportion of both nr-axSpA and AS pts treated with BKZ vs PBO achieved lower total and nocturnal spinal pain scores at Wk 16 (Figure 3). Pts treated with BKZ also achieved reductions from BL in mean total spinal pain, nocturnal spinal pain, and BASDAI morning stiffness scores to Wk 24, with separation from PBO observed at the first post-BL assessment (Wk 1; Figure 1). Responses at Wk 24 for pts who switched from PBO to BKZ at Wk 16 approached those seen in BKZ-randomized pts.

Similarly, at Wk 16 a higher proportion of pts achieved ≥4-point improvement in FACIT-Fatigue score with BKZ vs PBO (nr-axSpA: 70.3% vs 45.2%; AS: 66.1% vs 49.5%). Improvement in FACIT-Fatigue scores to Wk 24 were also observed across nr-axSpA and AS pts treated with BKZ, with separation from PBO at first post-BL assessment (Wk 4; Figure 2). Among pts who switched from PBO to BKZ at Wk 16, responses at Wk 24 approached those seen in BKZ-randomized pts.

Conclusion: Treatment with BKZ resulted in rapid and clinically relevant improvements in spinal pain, morning stiffness and fatigue in pts with active axSpA regardless of radiographic classification (AS and nr-axSpA) with separation from PBO at first post-BL assessment. These findings emphasize the benefit of BKZ for clinical symptoms which are important to pts and have significant impact on their daily lives.

References: 1. Deodhar A. Ann Rheum Dis 2022;81:772–3; 2. van der Heijde D. Ann Rheum Dis 2022;81:12–3; 3. Strand V. J Clin Rheumatol 2017;23:383–91.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: P. Mease, AbbVie, Amgen, Janssen, Novartis, Pfizer Inc, UCB, Sun Pharma, Eli Lilly, Bristol-Myers Squibb(BMS), Celgene, Genentech; A. Deodhar, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, UCB Pharma, Aurinia, Moonlake; M. Dougados, Novartis, AbbVie, Eli Lilly, Merck, Pfizer, UCB Pharma; M. Dubreuil, Amgen, UCB Pharma, Pfizer; M. Magrey, AbbVie, Eli Lilly, Novartis, Pfizer Inc, UCB; H. Marzo-Ortega, None; M. Rudwaleit, AbbVie, Bristol-Myers Squibb (BMS), Boehringer-Ingelheim, Chugai, Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma; C. de la Loge, UCB Pharma; A. Ellis, UCB Pharma; C. Fleurinck, UCB Pharma; M. Oortgiesen, UCB Pharma; V. Taieb, UCB Pharma; L. Gensler, Novartis, Pfizer Inc, UCB Pharma, AbbVie, Eli Lilly, Janssen, Gilead, Moonlake.

To cite this abstract in AMA style:

Mease P, Deodhar A, Dougados M, Dubreuil M, Magrey M, Marzo-Ortega H, Rudwaleit M, de la Loge C, Ellis A, Fleurinck C, Oortgiesen M, Taieb V, Gensler L. Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/bimekizumab-improves-key-patient-reported-symptoms-of-axial-spondyloarthritis-including-spinal-pain-and-fatigue-results-from-two-phase-3-studies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bimekizumab-improves-key-patient-reported-symptoms-of-axial-spondyloarthritis-including-spinal-pain-and-fatigue-results-from-two-phase-3-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology